An observational study in Hypoxemia, sponsored by Nihon Kohden. Enrolling by invitation at 1 site in United States. Open to participants aged 0 Days to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-21.
Sponsored by Nihon Kohden · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Hypoxia by Nihon Kohden — 2 open to participants now, 4 under way, none of them phase 3. Hypoxia · Nihon Kohden.
Among the 10 studies in Hypoxia by Nihon Kohden, this one has the largest planned enrollment, is one of 2 that started in 2025, is one of 10 observational ones, and was the 8th registered.
1,081 studies on the registry are indexed under Hypoxia; 213 are open to participants now.
Browse Hypoxia studies →2 of the 10 studies in Hypoxia by Nihon Kohden are open now, in 1 country. Recruiting first, the newest first:
Nihon Kohden · Sites in United States
Ages 18–35 · Healthy volunteers
By country, each count listing its studies:
Of the 124 Hypoxia studies recruiting now, 52 (42%) set no upper age limit and 46 (37%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 0 Days to 12 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 180 is above the median of 79 across 279 observational studies indexed under Hypoxia.
Median enrollment 12 across the 10 observational studies. Of the 6 that completed or were terminated, 6 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
Nihon Kohden is the lead sponsor of 16 studies on the registry; 3 are open to participants now.
3 of the studies in Hypoxia by Nihon Kohden that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07408388Nihon KohdenPulse Oximeter Accuracy During Stable Hypoxia Plateaus | 2026-12-01 |
| NCT07503171Nihon KohdenHypoxia and Hemodilution Testing in Healthy Adult Volunteers | 2027-02-01 |
| NCT07168798Nihon KohdenSpO2 Accuracy in Children | 2027-11-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 10 studies in Hypoxia by Nihon Kohden, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Evaluation of SpO2 Accuracy in Children with Various Skin Color
Pulse oximeters, which estimate blood oxygen levels, are routinely utilized for monitoring. However, research has shown that these devices may provide higher readings for individuals with darker skin tones as compared to individuals with lighter skin tones. This inaccuracy can result in unnoticed or untreated low oxygen levels, particularly affecting racial and ethnic minorities. It is beneficial for patients and healthcare providers to evaluate the accuracy of pulse oximeter oxygen saturation (SpO2) readings from pulse oximeters sold in the U.S. This study test the Nihon Kohden pulse oximeter and SpO2 sensors in neonatal and pediatric patients.
Children in hospital setting
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects who meet the enrollment criteria
Device: Pulse oximeter
OLV-4201 pulse oximeter with sensors: TL-272T3, TL-274T3 and TL-273T3
SpO2 accuracy
Evaluate the accuracy of Nihon Kohden SpO2 in measuring blood oxygen levels in children with varying skin tones
Time frame: 24 hours
SpO2 to SaO2 agreement
Evaluate the agreement between Nihon Kohden SpO2 and arterial oxygen saturation (SaO2) in children with varying skin tones
Time frame: 24 hours
Plan to share: No — Proprietary information
Started Nov 2025 (actual). Primary completion is estimated for Nov 2027, 23 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nihon Kohden